Moderna's October Data Drop and November Earnings Give Investors Two Separate Tests

Moderna shares fell 8.0% on Friday as profit-taking set in following a rally driven by optimism over the company's cancer vaccine program. Media reports pointed to a more cautious tone on Wall Street, valuation concerns and Goldman Sachs' neutral stance as contributing factors. The pullback reflects tempered expectations after a sharp run-up rather than any verdict on the science.

Goldman Sachs analyst Salveen Richter raised her price target on Moderna from $120 to $137, keeping her rating at "Neutral." The higher target did not come with a more positive recommendation — a distinction that matters when reading Friday's retreat. The combination suggests a nuanced view: the analyst lifted her mark but stopped short of turning bullish. No specific rationale for the move was given.

That split between a higher target and a neutral rating fits neatly with the valuation worries cited as a drag on Friday's trading. A price target increase alone does not confirm every level the stock previously reached, just as one weak session does not invalidate the expectations behind the earlier advance. What matters is how much progress is already baked into the price.

October 24 Looms as the First Real Test

The near-term focus is the upcoming presentation of Phase 3 data from the INTerpath-001 study. Moderna and Merck plan to unveil detailed results for intismeran autogene in combination with Keytruda on October 24 at the ESMO congress. Moderna has also scheduled an investor call for the same day, putting both the scientific findings and management's explanation of them on the agenda.

The confirmed date offers a concrete checkpoint for expectations — but no advance judgment on the outcome. Neither a positive study result nor its commercial value can be inferred from the presentation being scheduled. Investors would do well to keep that separation in mind rather than treating the data drop as a foregone success.

Insider Sales and a November Date

Separately, a Form 4 filing documents share sales by Moderna President Stephen Hoge on Wednesday and Thursday, alongside option exercises on both days. The disclosure confirms transactions but carries no statement from Hoge on valuation or the pending study data, and it offers no explanation for Friday's decline. The sales should be weighed apart from the market moves and the analyst decision.

Moderna also announced on Tuesday that it will report third-quarter 2026 results on November 6, together with a corporate update.

That leaves investors with a sequence of distinct checkpoints: the study details first, then the financials and management commentary. They answer different questions and should not be treated as interchangeable stock catalysts. The more telling question is not whether Friday's slide is quickly reversed, but whether the coming disclosures support the expectations embedded in the valuation. For now, the session showed above all that a rally and a higher analyst target do not settle the valuation question.